In a phase II ‘basket’ study of 122 patients with different BRAF V600-mutated cancers treated with vemurafenib [71], some positive survival results were reported, including two patients with pancreatic cancer (one of whom had stable disease for seven months and the other progressed and died within one month). Here, BRAF is linked to pancreatic neoplasm.